The use of angiotensin-converting enzyme inhibitors in hospitalized patients with COVID-19 is associated with a lower risk of mortality

Abstract The relationship between the use of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs), diabetes mellitus (DM), and the risk of death in patients with COVID-19 remains controversial. We hypothesized that DM and certain characteristics of the COVID-1...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Mykola Khalangot, Vitaliy Gurianov, Tamara Zakharchenko, Victor Kravchenko, Olena Kovzun, Volodymyr Shupachynskiy, Mykola Tronko
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Nature Portfolio 2025-11-01
Serie:	Scientific Reports
Soggetti:	COVID-19 RAAS inhibitors Diabetes mellitus Angiotensin-converting-enzyme inhibitors (ACEIs) Angiotensin II receptor blockers (ARBs) Mortality
Accesso online:	https://doi.org/10.1038/s41598-025-29757-x
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!